A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of RMC-4630 Monotherapy in Adult Participants With Relapsed/Refractory Solid Tumors

This study is testing a new experimental drug called RMC-4630 to see if it can help stop or slow the growth of solid tumors, like those found in the lungs or colon. The main goal is to find the safest and most effective dose of this medicine for people whose cancer has not responded to standard treatments.

This trial is for adults (18+) with advanced solid tumors that have specific genetic changes, known as KRAS, BRAF, or NF1 mutations. To participate, you must be healthy enough to perform daily activities and have organ functions that are working well enough to safely handle the new medication.

As this is a Phase 1 study, you will receive the experimental drug while doctors closely monitor your health to see how your body reacts to it. You will undergo regular check-ups, blood tests, and scans to ensure the treatment is safe and to track how your tumor responds.

The study is currently taking place at medical centers in Scottsdale, Arizona, and Duarte and Orange, California. The study status is currently listed as unknown, so it is best to contact the clinical sites directly to see if they are still accepting new patients.